Shebli Atrash

2.0k total citations
119 papers, 752 citations indexed

About

Shebli Atrash is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Shebli Atrash has authored 119 papers receiving a total of 752 indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Hematology, 53 papers in Oncology and 46 papers in Molecular Biology. Recurrent topics in Shebli Atrash's work include Multiple Myeloma Research and Treatments (91 papers), Protein Degradation and Inhibitors (33 papers) and CAR-T cell therapy research (24 papers). Shebli Atrash is often cited by papers focused on Multiple Myeloma Research and Treatments (91 papers), Protein Degradation and Inhibitors (33 papers) and CAR-T cell therapy research (24 papers). Shebli Atrash collaborates with scholars based in United States, Jordan and United Kingdom. Shebli Atrash's co-authors include Saad Z. Usmani, Peter M. Voorhees, Manisha Bhutani, David Foureau, Al‐Ola Abdallah, Bart Barlogie, Frits van Rhee, Sarah Waheed, Christoph Heuck and John Crowley and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shebli Atrash

99 papers receiving 743 citations

Peers

Shebli Atrash
Abdul Hamid Bazarbachi United States
Susan Bal United States
Larysa Sanchez United States
Jenna D. Goldberg United States
Antonio Capaldi Italy
Luis Gerardo Rodríguez‐Lobato Spain
Matteo Da Vià Italy
Alexandra Croockewit Netherlands
Donna Reece Canada
M.V. Mateos Spain
Abdul Hamid Bazarbachi United States
Shebli Atrash
Citations per year, relative to Shebli Atrash Shebli Atrash (= 1×) peers Abdul Hamid Bazarbachi

Countries citing papers authored by Shebli Atrash

Since Specialization
Citations

This map shows the geographic impact of Shebli Atrash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shebli Atrash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shebli Atrash more than expected).

Fields of papers citing papers by Shebli Atrash

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shebli Atrash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shebli Atrash. The network helps show where Shebli Atrash may publish in the future.

Co-authorship network of co-authors of Shebli Atrash

This figure shows the co-authorship network connecting the top 25 collaborators of Shebli Atrash. A scholar is included among the top collaborators of Shebli Atrash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shebli Atrash. Shebli Atrash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mansour, Razan, Nausheen Ahmed, Muhammad Umair Mushtaq, et al.. (2025). Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience. Clinical Lymphoma Myeloma & Leukemia. 26(2). 94–105.
2.
3.
Atrash, Shebli, Abdullah Khan, Hira Shaikh, et al.. (2025). Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals. Cancers. 17(21). 3569–3569.
4.
Atrash, Shebli, et al.. (2024). Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy. 30(3). 253–254. 1 indexed citations
5.
Shaikh, Hira, James A. Davis, Nausheen Ahmed, et al.. (2024). P-079 Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S87–S88. 1 indexed citations
6.
Hamadeh, Issam S., et al.. (2024). Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma. Frontiers in Oncology. 14. 1455464–1455464. 3 indexed citations
7.
Davis, James, Donald C. Moore, Charlotte B Wagner, et al.. (2024). Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 144(Supplement 1). 2382–2382. 1 indexed citations
8.
Shaikh, Hira, Christopher Strouse, James A. Davis, et al.. (2024). Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial. Blood. 144(Supplement 1). 2411.2–2411.2. 1 indexed citations
9.
10.
Ehsan, Hamid, Myra Robinson, Peter M. Voorhees, et al.. (2024). Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life. 14(3). 384–384. 2 indexed citations
11.
Ahmed, Nausheen, Anuj Shrestha, Faiz Anwer, et al.. (2024). TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians. Transplantation and Cellular Therapy. 30(9). 925.e1–925.e6. 2 indexed citations
12.
Bhutani, Manisha, David Foureau, Myra Robinson, et al.. (2023). A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. Clinical Lymphoma Myeloma & Leukemia. 23(7). 535–544.e1. 2 indexed citations
13.
Abdallah, Al‐Ola, Ghulam Rehman Mohyuddin, Nausheen Ahmed, et al.. (2021). Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. SHILAP Revista de lepidopterología. 2(4). 757–764. 4 indexed citations
14.
Patel, Jai N., Myra Robinson, Megan H. Jagosky, et al.. (2020). Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug–Based Regimens. Clinical Lymphoma Myeloma & Leukemia. 21(3). 188–198.e2. 5 indexed citations
15.
Moore, Donald C., Justin Arnall, Barry Paul, et al.. (2020). Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. Clinical Lymphoma Myeloma & Leukemia. 20(10). e777–e781. 10 indexed citations
16.
Hamadeh, Issam S., Justin Arnall, Shebli Atrash, et al.. (2020). Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. Clinical Lymphoma Myeloma & Leukemia. 20(8). 526–532.e1. 15 indexed citations
17.
Abdallah, Al‐Ola, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, et al.. (2020). Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(2). e212–e219. 3 indexed citations
18.
Robinson, Myra, Shebli Atrash, Jared Block, et al.. (2017). Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma. Blood. 130. 4348–4348.
19.
Bhutani, Manisha, David Foureau, Qing Zhang, et al.. (2017). Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases. Blood. 130. 3054–3054. 2 indexed citations
20.
Foureau, David, Manisha Bhutani, Qing Zhang, et al.. (2017). Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma. Blood. 130. 1817. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abdul Hamid Bazarbachi Breakdown of academic impact, for papers by Susan Bal Breakdown of academic impact, for papers by Larysa Sanchez Breakdown of academic impact, for papers by Jenna D. Goldberg Breakdown of academic impact, for papers by Antonio Capaldi Breakdown of academic impact, for papers by Luis Gerardo Rodríguez‐Lobato Breakdown of academic impact, for papers by Matteo Da Vià Breakdown of academic impact, for papers by Alexandra Croockewit Breakdown of academic impact, for papers by Donna Reece Breakdown of academic impact, for papers by M.V. Mateos
Rankless by CCL
2026